Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/9587
Title: Integrase strand transfer inhibitors (INSTIS) resistance mutations in HIV-1 infected Turkish patients
Authors: Sayan, M.
Gündüz, A.
Ersöz, G.
İnan, A.
Deveci, A.
Özgür, G.
Sargın, F.
Keywords: DNA sequencing
Dolutegravir
Drug resistance
Elvitegravir
HIV-1 integrase
Integrase inhibitors
Raltegravir
anti human immunodeficiency virus agent
elvitegravir
integrase
integrase strand transfer inhibitor
proteinase
raltegravir
RNA directed DNA polymerase
unclassified drug
virus RNA
codon
integrase inhibitor
adult
Article
CD4+ T lymphocyte
cytomegalovirus infection
delta agent hepatitis
female
hepatitis B
hepatitis C
human
Human immunodeficiency virus 1
Human immunodeficiency virus 1 infection
Human immunodeficiency virus infected patient
lung tuberculosis
major clinical study
male
mixed infection
priority journal
Pseudomonas pneumonia
structural gene
thrush
toxoplasmosis
Turkish citizen
virus detection
virus mutation
aged
amino acid substitution
antiviral resistance
CD4 lymphocyte count
drug effects
genetics
genotype
HIV Infections
microbial sensitivity test
middle aged
mutation
risk factor
transmission
Turkey
virology
virus load
young adult
Adult
Aged
Amino Acid Substitution
CD4 Lymphocyte Count
Codon
Coinfection
Drug Resistance, Viral
Female
Genotype
HIV Integrase Inhibitors
HIV-1
Humans
Male
Microbial Sensitivity Tests
Middle Aged
Mutation
Risk Factors
RNA, Viral
Viral Load
Young Adult
Publisher: Taylor and Francis Ltd.
Abstract: Objectives: Integrase strand transfer inhibitor (INSTI) is a new class of antiretroviral (ARV) drugs designed to block the action of the integrase viral enzyme, which is responsible for insertation of the HIV-1 genome into the host DNA. The aim of this study was to evaluate for the first time INSTI resistance mutations in Turkish patients. Methods: This study was conducted in Turkey, between April 2013 and April 2015 using 169 HIV-1-infected patients (78 ARV naive patients and 91 ARV-experienced patients). Laboratory and clinical characteristics of ARV naive and ARV-experienced patients were as follows: gender (M/F): 71/7 and 80/11, median age: 38 and 38.4; median CD4+ T-cell: 236 and 216 cells/mm3, median HIV-1 RNA: 4.95+E5 and 1.08E+6 copies/ml. Population-based seqeunces of the reverse transcriptase, protease, and integrase domains of the HIV-1 pol gene were used to detect HIV-1 drug resistance mutations. Result: INSTI resistance mutations were not found in recently diagnosed HIV-1-infected patients. However, ARV-experienced patients had major resistance mutations associated with raltegravir and elvitegravir; the following results were generated:F121Y, Y143R, Q148R and E157Q (6/91 – 6.6%). Conclusions: The prevalence of INSTI resistant mutations in ART-experienced patients suggested that resistance testing must be incorporated as an integral part of HIV management with INSTI therapies. © 2016 Informa UK Limited, trading as Taylor & Francis Group.
URI: https://hdl.handle.net/11499/9587
https://doi.org/10.1080/15284336.2016.1153303
ISSN: 1528-4336
Appears in Collections:PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

Show full item record



CORE Recommender

SCOPUSTM   
Citations

7
checked on Nov 30, 2024

WEB OF SCIENCETM
Citations

10
checked on Dec 4, 2024

Page view(s)

28
checked on Aug 24, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.